Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Role of BAP1 in Tumorigenesis and Metastasis in Uveal and Cutaneous Melanoma

FY 2010-11

Summary
The World Health Organization estimates that 2-3 million non-melanoma and 132,000 melanoma skin cancers are diagnosed worldwide each year. Skin cancer is the most common cancer in Canada. In 2009, melanoma constituted only 6% of reported skin cancers cases, but was responsible for 78% of skin cancer-related deaths, according to the Canadian Cancer Society. With early detection, surgical excision is curative for patients diagnosed with cutaneous melanoma. However, patients with metastatic melanoma in which tumor cells spread to distal sites in the skin, lymph nodes and other organs, have a median survival of 6-9 months. Furthermore, uveal melanoma is the most common malignancy of the eye, and accounts for 5% of all melanoma cases. Approximately 50% of these patients succumb to metastasic disease. Recently, a study demonstrated that over 80% of patients with metastatic uveal melanoma have mutations in the BAP1 gene. During my Fellowship, I will work to identify how mutations in BAP1 lead to spreading of uveal tumor cells to distal organs in the body and determine whether this similarly occurs in cutaneous melanoma. I will also develop a preclinical mouse model of uveal and cutaneous melanoma by recapitulating the cancer-associated mutations in the BAP1 gene in the mouse. By understanding how BAP1 mutations lead to melanoma metastasis we will identify novel therapeutic avenues to limit metastasic spread of cancer cells. These therapies will be tested in our pre-clinical mouse model with the goal of translating our discoveries into improved detection and treatment for Canadian patients suffering from this disease.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
227278
Name
Watson Ian R
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Role of BAP1 in Tumorigenesis and Metastasis in Uveal and Cutaneous Melanoma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Research; Deubiquitinating Enzymes; Genetically Engineered Mouse Models; Melanoma; Metastasis; Polycomb Group Protein; Stem Cell Fate; Therapeutic Targets; Tumor Suppressors; Uveal Melanoma
Abstract
The World Health Organization estimates that 2-3 million non-melanoma and 132,000 melanoma skin cancers are diagnosed worldwide each year. Skin cancer is the most common cancer in Canada. In 2009, melanoma constituted only 6% of reported skin cancers cases, but was responsible for 78% of skin cancer-related deaths, according to the Canadian Cancer Society. With early detection, surgical excision is curative for patients diagnosed with cutaneous melanoma. However, patients with metastatic melanoma in which tumor cells spread to distal sites in the skin, lymph nodes and other organs, have a median survival of 6-9 months. Furthermore, uveal melanoma is the most common malignancy of the eye, and accounts for 5% of all melanoma cases. Approximately 50% of these patients succumb to metastasic disease. Recently, a study demonstrated that over 80% of patients with metastatic uveal melanoma have mutations in the BAP1 gene. During my Fellowship, I will work to identify how mutations in BAP1 lead to spreading of uveal tumor cells to distal organs in the body and determine whether this similarly occurs in cutaneous melanoma. I will also develop a preclinical mouse model of uveal and cutaneous melanoma by recapitulating the cancer-associated mutations in the BAP1 gene in the mouse. By understanding how BAP1 mutations lead to melanoma metastasis we will identify novel therapeutic avenues to limit metastasic spread of cancer cells. These therapies will be tested in our pre-clinical mouse model with the goal of translating our discoveries into improved detection and treatment for Canadian patients suffering from this disease.
Competitiondate
201102
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Watson, Ian R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~